Aditya Bardia MD, MPH, FASCO

Dr. Aditya Bardia, MD, MPH, FASCO, is an internationally renowned breast oncologist known for his pioneering clinical and translational research in cancer therapeutics, particularly antibody drug conjugates. Dr. Bardia led the development of sacituzumab govitecan, the first ADC approved for patients with metastatic triple-negative breast cancer, as well as others, including trastuzumab deruxtecan and datapotamab deruxtecan. Dr. Bardia also led the clinical development of elacestrant, the first oral SERD approved for patients with metastatic HR+ positive breast cancer.

In translational collaboration with various labs, identified the role of ESR1 mutations in mediating endocrine resistance, RB1 mutations in mediating CDK 4/6i resistance, and TOP1 mutations in mediating ADC resistance. Besides cutting-edge research, Dr. Bardia is highly regarded among peers as an excellent mentor and strong advocate for academic trainees and junior faculty members. Dr. Bardia has received several awards, including the Outstanding Award for Research Excellence at Mayo Clinic, the Young Investigator Award from ASCO, the Distinguished Researcher Award from MASCO, and the Douglas Family Foundation Prize for Excellence in Oncology Research.